Doseadjusted EPOCH chemotherapy for untreated peripheral Tcell lymphomas

  • Slides: 6
Download presentation
Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of

Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL 0707 by Yoshinobu Maeda, Hisakazu Nishimori, Isao Yoshida, Yasushi Hiramatsu, Masatoshi Uno, Yasufumi Masaki, Kazutaka Sunami, Taro Masunari, Yuichiro Nawa, Hiromichi Yamane, Hiroshi Gomyo, Tsutomu Takahashi, Tomofumi Yano, Keitaro Matsuo, Koichi Ohshima, Shigeo Nakamura, Tadashi Yoshino, and Mitsune Tanimoto haematol Volume 102(12): 2097 -2103 November 30, 2017 © 2017 by Ferrata Storti Foundation

Patients’ characteristics. Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by

Patients’ characteristics. Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by Ferrata Storti Foundation

Map of dose levels achieved, according to cycle. Yoshinobu Maeda et al. Haematologica 2017;

Map of dose levels achieved, according to cycle. Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by Ferrata Storti Foundation

Adverse event of dose-adjusted-EPOCH treatment (total 255 cycles). Yoshinobu Maeda et al. Haematologica 2017;

Adverse event of dose-adjusted-EPOCH treatment (total 255 cycles). Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by Ferrata Storti Foundation

Kaplan-Meier estimates of progression-free and overall survival of patients with peripheral T-cell lymphomas (PTCLs)

Kaplan-Meier estimates of progression-free and overall survival of patients with peripheral T-cell lymphomas (PTCLs) receiving dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) (DA-EPOCH). Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by Ferrata Storti Foundation

Patients’ outcome. Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by

Patients’ outcome. Yoshinobu Maeda et al. Haematologica 2017; 102: 2097 -2103 © 2017 by Ferrata Storti Foundation

Doseadjusted EPOCH chemotherapy for untreated peripheral Tcell lymphomasDoseadjusted EPOCH chemotherapy for untreated peripheral Tcell lymphomas
DoseAdjusted EPOCH plus Rituximab in Untreated Patients withDoseAdjusted EPOCH plus Rituximab in Untreated Patients with
PERIPHERAL TCELL LYMPHOMAS HOW I MANAGE PTCL INPERIPHERAL TCELL LYMPHOMAS HOW I MANAGE PTCL IN
CD 30 positive peripheral Tcell lymphomas share molecularCD 30 positive peripheral Tcell lymphomas share molecular
Untreated GPR 37 L 1 GFAPa Untreated GPRUntreated GPR 37 L 1 GFAPa Untreated GPR